Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05894447
Title Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.